1Cools AR,Van Rossum JM.Excitation-mediating and inhibition-mediating dopamine-receptors:a new concept towards a better understanding of electrophysiological,biochemical,pharmacological,functional and clinical data.Psychopharmacologia,1976,45(3):243-254.
2Spano PF,Govoni S,Trabucchi M.Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system.Adv Biochem Psychopharmacol,1978,19:155-156.
3Kebabian JW,Calne DB.Kebabian PR.Lergotrile mesylate:an in vivo dopamine agonist which blocks dopamine receptors in vitro.Commun Psychopharmacol,1977,1(4):311-318.
4Plante-Bordeneuve V,Taussig D.Thomas F,et al.Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease:evidence for association of a DRD2 allele.Neurology,1997,48(6):1589-1593.
5Fishburn CS,Belleli D,David C,et al.A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop.J Biol Chem,1993,268(8):5872-5878.
7Giros B,Jaber M,Jones SR,et al.Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.Nature,1996,379(6566):606～612.
8Severnse DM,Colapietro AM,Box TL,et al.The human D1a dopamine receptor gene promoter directs expression of a receptor gene to the central nervous system in transgenic mice.Molec Brain Res,1995,30:336.
9Bergson C,Mrzljak L,Smiley JF,et al.Regional,cellular,and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain.J Neurosci,1995,15(12):7821～7836.
10Calabresi P,Saiardi A,Pisani A,et al.Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors.J Neurosci,1997,17(12):4536-4544.
2Schapira AH. Progress in neuroprotectice in Parkinson's disease. Eur J Neurol. 2008,15 (Suppl 1):.5-13.
3Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. Neurologist,2007,13(3): 126-1329.
4Muller T, Erdmann C, Muhlack S, et al. Entacapone improves complex movement performance in patients with Parkinson's disease,2007,14(5):424-428.
5Mizuno Y, Kanazawa I, Kuno S, et al. Placebocontrolled, double-blind dose-flnding study of entacapone in fluctuating parkinsonian patients. Mov Disord,2007,22(1):75-80.
6Muller T, Erdmann C, Muhlack S. et al. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord,2006,21 (3):332-336.
7Stocchi F, Barbato L, Nordera G, et al, Entacapone improves the pharmacoklnetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. J Neural Transm,2004,111(2): 173-180.
8Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol,2005,28(3): 115-119.
9Heikkinen H, Varhe A, Laine T, et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol,2002,54(4):363- 371.
10Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology, 2004, 62( Suppl 1):S39-46.
